Imexpharm Corporation (HOSE:IMP)

Vietnam flag Vietnam · Delayed Price · Currency is VND
45,000
+450 (1.01%)
At close: Apr 1, 2025
44.10%
Market Cap 6.93T
Revenue (ttm) 2.21T
Net Income (ttm) 297.54B
Shares Out 154.01M
EPS (ttm) 1,931.94
PE Ratio 23.29
Forward PE 18.60
Dividend 454.55 (1.02%)
Ex-Dividend Date Jul 11, 2024
Volume 98,100
Average Volume 348,775
Open 44,650
Previous Close 44,550
Day's Range 44,650 - 45,750
52-Week Range 29,136 - 56,500
Beta 0.97
RSI 40.91
Earnings Date Apr 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 1,452
Stock Exchange Ho Chi Minh Stock Exchange
Ticker Symbol IMP
Full Company Profile

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.

Financial Statements

News

There is no news available yet.